ENTA
Enanta Pharmaceuticals, Inc.
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Sell
-21/100
Last price
12.17
▼ 0.43 (3.41%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
12.66
Prev close
12.60
Day high
12.66
Day low
12.00
Volume
271.69K
Market cap
$354.46M
P/E (TTM)
—
52W range
10.20 – 17.15
Day trading desk
Gap from prior close
+0.48%
Prior close 12.60
VWAP
12.22
-0.42% from price
Relative volume
1.04×
Normal
Session range
5.50%
12.00 – 12.66
Position in range
26%
Near session low
ATR (14D)
0.55
4.51% of price
Prior day high
13.02
PDH
Prior day low
12.47
PDL
Bid / ask spread
—
Quote not published
Session volume
234.52K
Avg 225.98K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-3.72%
-5.7%
1M
-13.57%
-14.7%
3M
-16.01%
-20.5%
6M
-9.38%
-27.6%
YTD
-22.83%
-37.1%
1Y
+17.81%
+1.4%
3Y
+8.95%
-73.3%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on ENTA open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
1.36M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Feb 12, 26 | LULY JAY R Chief Executive Officer |
STOCK | 20.00K | $0 | Direct |
| Feb 12, 26 | OR YAT SUN Officer |
STOCK | 6.88K | $0 | Direct |
| Feb 12, 26 | KOWALSKY MATTHEW PAUL Officer |
STOCK | 5.49K | $0 | Direct |
| Feb 12, 26 | KIEFFER TARA LYNN Officer |
STOCK | 6.56K | $0 | Direct |
| Feb 12, 26 | LUU BRENDAN Officer |
STOCK | 6.56K | $0 | Direct |
| Feb 12, 26 | ROTTINGHAUS SCOTT T. Officer |
STOCK | 6.88K | $0 | Direct |
| Dec 5, 25 | LULY JAY R Chief Executive Officer |
SELL | 4.74K | $67.49K | Direct |
| Dec 5, 25 | TROUT HARRY R III Officer |
SELL | 542 | $7.71K | Direct |
| Dec 5, 25 | OR YAT SUN Officer |
SELL | 2.39K | $34.01K | Direct |
| Dec 5, 25 | KIEFFER TARA LYNN Officer |
SELL | 2.11K | $29.97K | Direct |
| Dec 5, 25 | LUU BRENDAN Officer |
SELL | 1.39K | $19.84K | Direct |
| Dec 5, 25 | ROTTINGHAUS SCOTT T. Officer |
SELL | 798 | $11.36K | Direct |
| Dec 5, 25 | CAPPS KATHLEEN S. CPA Officer |
SELL | 323 | $4.60K | Direct |
| Dec 2, 25 | TROUT HARRY R III Officer |
SELL | 380 | $5.30K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
CAPPS KATHLEEN S. CPA |
Officer | 8.38K | Sale |
KIEFFER TARA LYNN |
Officer | 33.92K | Stock Award(Grant) |
KOWALSKY MATTHEW PAUL |
Officer | 3.59K | Stock Award(Grant) |
LULY JAY R |
Chief Executive Officer | 871.87K | Stock Award(Grant) |
LUU BRENDAN |
Officer | 41.63K | Stock Award(Grant) |
MELLETT PAUL J JR |
Officer | 95.88K | Stock Award(Grant) |
OR YAT SUN |
Officer | 374.85K | Stock Award(Grant) |
ROTTINGHAUS SCOTT T. |
Officer | 25.25K | Stock Award(Grant) |
TROUT HARRY R III |
Officer | 16.35K | Sale |
Fundamentals
Market cap$354.46M
Enterprise value$346.99M
Revenue (TTM)$65.26M
Gross profit$65.26M
EBITDA$-53.82M
Net income$-63.23M
EPS (TTM)$-2.42
Free cash flow$-22.66M
Total cash$189.51M
Total debt$182.04M
Book value / share$3.47
Shares outstanding29.13M
Float22.52M
Short % of float10.68%
Dividend yield0.00%
Beta (5Y)0.96
Valuation & profitability ratios
Trailing P/E—
Forward P/E-5.13
PEG ratio—
Price / sales—
Price / book3.51
EV / revenue5.32
EV / EBITDA-6.45
Gross margin100.00%
Operating margin-120.04%
Profit margin-96.89%
Return on equity-70.12%
Return on assets-12.28%
Debt / equity180.12
Current ratio3.76
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $65.32M | $67.64M | $79.20M | $86.16M | -3.4% |
| Operating revenue | $65.32M | $67.64M | $79.20M | $86.16M | -3.4% |
| Research & development | $106.74M | $131.48M | $163.52M | $164.52M | -18.8% |
| Selling, general & admin | $43.93M | $57.85M | $52.89M | $45.48M | -24.1% |
| Total operating expense | $150.67M | $189.33M | $216.41M | $210.00M | -20.4% |
| Operating income | -$85.35M | -$121.69M | -$137.21M | -$123.84M | +29.9% |
| Net interest income | $1.76M | $3.83M | $6.21M | $1.57M | -54.0% |
| Pre-tax income | -$83.55M | -$117.79M | -$131.00M | -$122.19M | +29.1% |
| Tax provision | -$1.66M | -$1.74M | $2.82M | -$433.00K | +4.8% |
| Net income | -$81.89M | -$116.05M | -$133.82M | -$121.75M | +29.4% |
| Net income to common | -$81.89M | -$116.05M | -$133.82M | -$121.75M | +29.4% |
| Basic EPS | -3.84 | -5.48 | -6.38 | -5.91 | +29.9% |
| Diluted EPS | -3.84 | -5.48 | -6.38 | -5.91 | +29.9% |
| EBIT | -$75.87M | -$106.85M | -$125.85M | -$122.19M | +29.0% |
| EBITDA | -$71.28M | -$104.51M | -$123.48M | -$119.22M | +31.8% |
| Basic shares | 21.34M | 21.16M | 20.97M | 20.60M | +0.8% |
| Diluted shares | 21.34M | 21.16M | 20.97M | 20.60M | +0.8% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $32.30M | $37.23M | $85.39M | $43.99M | -13.3% |
| Cash & short-term investments | $188.86M | $248.19M | $369.91M | $249.23M | -23.9% |
| Accounts receivable | $6.88M | $6.65M | $8.61M | $20.32M | +3.6% |
| Total current assets | $204.34M | $299.85M | $422.79M | $311.71M | -31.9% |
| Property, plant & equipment | $72.94M | $73.35M | $34.71M | $29.75M | -0.5% |
| Total assets | $280.73M | $376.65M | $462.27M | $375.41M | -25.5% |
| Total current liabilities | $48.55M | $57.53M | $62.79M | $29.83M | -15.6% |
| Total debt | $57.90M | $55.47M | $26.51M | $25.26M | +4.4% |
| Total liabilities | $216.01M | $247.84M | $245.54M | $54.08M | -12.8% |
| Retained earnings | -$404.93M | -$323.04M | -$207.00M | -$73.18M | -25.3% |
| Shareholder equity | $64.72M | $128.81M | $216.74M | $321.33M | -49.8% |
| Working capital | $155.78M | $242.32M | $360.00M | $281.89M | -35.7% |
| Net tangible assets | $64.72M | $128.81M | $216.74M | $321.33M | -49.8% |
| Shares issued | 21.39M | 21.19M | 21.06M | 20.79M | +0.9% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$81.89M | -$116.05M | -$133.82M | -$121.75M | +29.4% |
| Depreciation & amortisation | $4.59M | $2.34M | $2.37M | $2.97M | +96.3% |
| Stock-based compensation | $18.57M | $26.80M | $28.22M | $26.97M | -30.7% |
| Change in working capital | $39.91M | $7.13M | $8.02M | $6.79M | +459.7% |
| Operating cash flow | -$19.27M | -$78.76M | -$103.15M | -$84.78M | +75.5% |
| Capital expenditure | -$12.90M | -$17.95M | -$9.06M | -$2.13M | +28.1% |
| Investing cash flow | $40.35M | $58.23M | -$53.58M | $54.90M | -30.7% |
| Financing cash flow | -$26.62M | -$27.63M | $198.13M | $20.03M | +3.6% |
| Free cash flow | -$32.17M | -$96.71M | -$112.21M | -$86.91M | +66.7% |
| End cash position | $35.66M | $41.20M | $89.36M | $47.96M | -13.5% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $14.36M | $17.16M | $18.61M | $15.13M | $18.31M | -16.3% |
| Operating revenue | $14.36M | $17.16M | $18.61M | $15.13M | $18.31M | -16.3% |
| Research & development | $22.13M | $19.44M | $20.86M | $23.81M | $27.21M | +13.8% |
| Selling, general & admin | $9.47M | $9.57M | $9.01M | $9.70M | $10.00M | -1.0% |
| Total operating expense | $31.59M | $29.01M | $29.87M | $33.51M | $37.21M | +8.9% |
| Operating income | -$17.24M | -$11.85M | -$11.25M | -$18.39M | -$18.89M | -45.4% |
| Net interest income | -$2.23M | -$1.23M | -$661.00K | -$321.00K | $667.00K | -80.9% |
| Pre-tax income | -$19.46M | -$13.08M | -$11.91M | -$18.67M | -$18.23M | -48.8% |
| Tax provision | $36.00K | $7.00K | $24.00K | $32.00K | $29.00K | +414.3% |
| Net income | -$19.50M | -$13.09M | -$11.94M | -$18.70M | -$18.25M | -49.0% |
| Net income to common | -$19.50M | -$13.09M | -$11.94M | -$18.70M | -$18.25M | -49.0% |
| Basic EPS | -0.67 | -0.45 | -0.42 | -0.87 | -0.85 | -48.9% |
| Diluted EPS | -0.67 | -0.45 | -0.42 | -0.87 | -0.85 | -48.9% |
| EBIT | -$15.34M | -$9.77M | -$8.83M | -$16.28M | -$16.61M | -57.0% |
| EBITDA | -$14.15M | -$8.56M | -$7.60M | -$15.00M | -$15.40M | -65.3% |
| Basic shares | 29.09M | 29.04M | 28.75M | 21.38M | 21.38M | +0.2% |
| Diluted shares | 29.09M | 29.04M | 28.75M | 21.38M | 21.38M | +0.2% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $33.42M | $34.93M | $37.44M | $32.30M | $44.81M | -4.3% |
| Cash & short-term investments | $189.51M | $163.77M | $185.85M | $188.86M | $204.11M | +15.7% |
| Accounts receivable | $6.53M | $7.81M | $8.49M | $6.88M | $8.33M | -16.3% |
| Total current assets | $203.62M | $178.41M | $198.68M | $204.34M | $222.71M | +14.1% |
| Property, plant & equipment | $67.79M | $69.55M | $71.31M | $72.94M | $74.87M | -2.5% |
| Total assets | $296.87M | $314.70M | $329.50M | $280.73M | $301.03M | -5.7% |
| Total current liabilities | $54.17M | $46.44M | $44.73M | $48.55M | $44.55M | +16.6% |
| Total debt | $55.66M | $56.54M | $57.07M | $57.90M | $58.05M | -1.6% |
| Total liabilities | $195.80M | $198.12M | $202.91M | $216.01M | $221.75M | -1.2% |
| Retained earnings | -$449.46M | -$429.96M | -$416.87M | -$404.93M | -$386.23M | -4.5% |
| Shareholder equity | $101.07M | $116.59M | $126.59M | $64.72M | $79.28M | -13.3% |
| Working capital | $149.45M | $131.97M | $153.96M | $155.78M | $178.16M | +13.2% |
| Net tangible assets | $101.07M | $116.59M | $126.59M | $64.72M | $79.28M | -13.3% |
| Shares issued | 29.12M | 29.06M | 29.02M | 21.39M | 21.38M | +0.2% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$19.50M | -$13.09M | -$11.94M | -$18.70M | -$18.25M | -49.0% |
| Depreciation & amortisation | $1.19M | $1.21M | $1.23M | $1.28M | $1.21M | -2.0% |
| Stock-based compensation | $3.68M | $3.75M | $3.81M | $4.03M | $4.18M | -1.7% |
| Change in working capital | $2.52M | -$49.00K | -$2.88M | $5.38M | $32.30M | +5,240.8% |
| Operating cash flow | -$9.97M | -$7.16M | -$11.70M | -$6.49M | $17.51M | -39.4% |
| Capital expenditure | -$7.00K | -$15.00K | -$143.00K | -$1.46M | -$155.00K | +53.3% |
| Investing cash flow | $14.01M | $11.94M | -$47.30M | $2.30M | -$26.48M | +17.3% |
| Financing cash flow | -$5.54M | -$7.29M | $64.14M | -$8.32M | -$6.42M | +24.0% |
| Free cash flow | -$9.98M | -$7.17M | -$11.84M | -$7.95M | $17.35M | -39.2% |
| End cash position | $36.78M | $38.29M | $40.80M | $35.66M | $48.17M | -3.9% |
Options analytics
Put / call volume
1.38
Put-heavy session
Put / call open interest
0.63
Positioning, not flow
Max pain
15.00
+23.3% from spot
ATM implied vol
6.3%
Nearest strike to spot
Skew (10% OTM)
+18.7%
Puts bid over calls
Call volume
8
Contracts, this expiry
Put volume
11
Contracts, this expiry
Heaviest call OI
17.50
11 contracts
Heaviest put OI
12.50
9 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.54 | -0.67 | -25.2% |
| Mar 2026 | -0.57 | -0.45 | +20.8% |
| Dec 2025 | -0.80 | -0.42 | +47.8% |
| Sep 2025 | -1.01 | -0.87 | +13.9% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.77 | 5 | $15.72M | +3.9% |
| Next quarter | -0.41 | 2 | $16.25M | -12.7% |
| Current year | -2.29 | 4 | $64.00M | -2.0% |
| Next year | -2.37 | 5 | $63.74M | -0.4% |
Analyst targets & ownership
Mean target$21.83
High target$32.00
Low target$19.00
Implied upside79.40%
Analyst count6
ConsensusSTRONG BUY
Strong buy / Buy1 / 5
Hold0
Sell / Strong sell0 / 0
Held by insiders4.67%
Held by institutions94.39%
Institutions holding178
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
12.48
-2.51% from price
SMA 20
12.55
-3.06% from price
SMA 50
13.09
-7.00% from price
SMA 100
13.12
-7.26% from price
SMA 200
13.47
-9.68% from price
EMA 12
12.59
-3.32% from price
EMA 26
12.76
-4.66% from price
EMA 50
12.97
-6.16% from price
RSI (14)
42.6
Neutral
MACD (12,26,9)
-0.18
Hist 0.04
ATR (14)
0.55
4.51% of price
Realised vol 30D
44.6%
Annualised
Bollinger upper
13.37
20, 2σ
Bollinger lower
11.74
20, 2σ
50 / 200 cross
Death
13.09 vs 13.47
Trend bias
Below 200
-9.68%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.86
Less volatile than market
Correlation to SPY
0.23
Largely independent
Realised vol 30D
44.6%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-34.3%
Peak to trough
Max drawdown 5Y
-95.6%
Peak to trough
ATR 14
0.55
4.51% of price
Beta (reported)
0.96
5Y monthly, from filing
Short interest
Shares short
2.60M
Prior 2.68M
Change vs prior
-3.0%
Shorts covering
% of float
10.68%
Elevated
% of shares out
8.93%
Against total outstanding
Days to cover
10.2
Crowded exit
Float
22.52M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 23, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jun 23, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Feb 10, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jan 9, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Nov 14, 25 | JP Morgan | INITIATED | — | Overweight |
| Sep 30, 25 | WestPark Capital | MAINTAINED | Buy | Buy |
| Sep 15, 25 | Evercore ISI Group | MAINTAINED | Outperform | Outperform |
| Sep 2, 25 | WestPark Capital | INITIATED | — | Buy |
| Aug 12, 25 | JMP Securities | MAINTAINED | Market Outperform | Market Outperform |
| Jun 3, 25 | JMP Securities | MAINTAINED | Market Outperform | Market Outperform |
| May 14, 25 | JMP Securities | MAINTAINED | Market Outperform | Market Outperform |
| Feb 11, 25 | JMP Securities | MAINTAINED | Market Outperform | Market Outperform |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Periodic Financial Reports
10-Q · 2026-08-12
Corporate Changes & Voting Matters
8-K · 2026-08-10
Corporate Changes & Voting Matters
8-K · 2026-07-02
Corporate Changes & Voting Matters
8-K · 2026-06-23
Corporate Changes & Voting Matters
8-K · 2026-06-18
Offering Registrations
S-8 · 2026-05-13
Corporate Changes & Voting Matters
8-K · 2026-05-11
Corporate Changes & Voting Matters
8-K · 2026-03-26
Headlines
Enanta Pharmaceuticals to Participate in September Investor Conferences
Business Wire · 36d ago
Enanta Pharmaceuticals (ENTA) Reports Q3 Loss, Lags Revenue Estimates
Zacks · 57d ago
Enanta Pharmaceuticals: Fiscal Q3 Earnings Snapshot
Associated Press · 57d ago
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2026
Business Wire · 57d ago
Nuvation Bio (NUVB) Soars 7.9%: Is Further Upside Left in the Stock?
Zacks · 78d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.